TD Cowen analyst Phil Nadeau has maintained their bullish stance on EDIT stock, giving a Buy rating on May 5.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Phil Nadeau’s rating is based on the promising advancements and strategic focus of Editas Medicine in the field of in vivo gene editing. The company has demonstrated significant preclinical proof-of-concept data that supports the potential of its in vivo editing technology. This includes robust gene editing and functional upregulation across various tissue types and animal models, which suggests a strong foundation for future clinical applications.
Additionally, Editas is on track to achieve several key milestones, including the nomination of two in vivo editing development candidates by mid-2025 and establishing human proof-of-concept for at least one program by the end of 2026. The upcoming presentations at major conferences like ASGCT and TIDES USA further underline the company’s commitment to advancing its technology and provide additional validation of its approach. These factors collectively contribute to the Buy rating, reflecting confidence in the company’s strategic direction and technological capabilities.
In another report released on May 5, H.C. Wainwright also maintained a Buy rating on the stock with a $3.00 price target.